Claims:

1. The use of a lipopeptide or lipoprotein of the structure (I)



(I)

where
R_1 and R_2, which may be identical or different, are C_{7-25}-alkyl, C_{7-25}-alkenyl or C_{7-25}-alkynyl,
X is S, O or CH_2,
R_3 and R_4 are independently of one another H or methyl and
Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,
and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Ingold-Prelog rule, when X is S (sulfur),
as mucosal adjuvant in therapeutic or prophylactic vaccination via the mucous membranes.

2. The use as claimed in claim 1, characterized in that the amino acid sequence Y is preferably selected from.
a) GQTNT
b) SKKKK
c) GNNDESNISFKEK
d) GQTDNNSSQSAAPGSGTTNT,

3. The use as claimed in claim 1 or 2, characterized in that the lipoprotein or lipopeptide of structure (I) is an S-[2,3-

bispalmitoyloxy(2*R*)propyl]cysteinyl-peptide, where the peptide is a physiologically tolerated amino acid sequence which consists of 1 to 25 amino acid residues and is preferably not immunogenic in the species used.

4. The use as claimed in any of claims 1 to 3, characterized in that the mucosal adjuvant is present in a preparation with the actual vaccine component which is intended for intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral administration or administration into the milk ducts of the female breast.

5. The use as claimed in any of claims 1 to 3, characterized in that the mucosal adjuvant is present in a kit for coadministration with a vaccine into the milk ducts of the female breast, by the intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral route.

6. The use of a lipopeptide or lipoprotein of the general structure (I)



(I)

where

R_1 and R_2, which may be identical or different, are C_{7-25}-alkyl, C_{7-25}-alkenyl or C_{7-25}-alkynyl,

X is S, O or CH_2,

R_3 and R_4 are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,

and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Ingold-Prelog rule, when X is S (sulfur),

excepting an S-(2,3-diacyloxypropyl)cysteine-peptide of the sequence DhcGNNDESNISFKEK, where N-terminally the amino acids at positions 2 and, where appropriate, 3 are absent, and/or C-terminally 1 to 2 amino acids may be deleted,

as adjuvant in a non-mucosal vaccination.

7. The use as claimed in any of claims 1 to 6, characterized in that the lipopeptide or lipoprotein is present in a preparation with at least one further adjuvant and/or antigen.

8. The use as claimed in any of claims 1 to 7, characterized in that the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

9. The use as claimed in any of claims 1 to 8, characterized in that the lipopeptide or lipoprotein is administered together with one or more anti-inflammatory, antiangiogenic, cytotoxic or immunomodulatory substances or ligands or with antibodies, or is present with these in a preparation.

10. The use as claimed in any of claims 1 to 9, characterized in that the lipopeptide or lipoprotein is present in a preparation which comprises further additives and excipients, in particular preservatives or stabilizers.

11. The use as claimed in any of claims 1 to 10, characterized in that the vaccine which is accompanied by the adjuvant, in the form of peptides, proteins, DNA, polysaccharides, glycolipids or glucoproteins.